Society of Gynecologic Oncology Publications
- In 2020, nearly 314,000 women worldwide were diagnosed with epithelial ovarian, fallopian tube and primary peritoneal carcinoma (“ovarian cancer”) and nearly 207,000 succumbed to this disease . Surgical cytoreduction and systemic chemotherapy are the cornerstones of frontline treatment for patients with advanced disease . Aggressive surgical efforts aimed at resection of all macroscopic disease and advances in systemic therapy have improved the survival of patients with advanced ovarian cancer.
- Venous thromboembolism (VTE) is a common cause of morbidity and mortality in women with gynecologic malignancies. This practice statement provides clinical data and overall quality of evidence regarding the use of direct oral anticoagulants (DOACs) in this patient population. Specifically, it reviews patient selection, safety measures, and nuances of perioperative use of these medications. The scope of this document is limited to DOAC use in gynecologic oncology rather than a broad discussion of VTE prophylaxis and management in general.
- The World Health Organization defines a patient's social determinants of health to be “the conditions in which people are born, grow, live, work, and age. These circumstances are inextricably linked to their unmet social needs and are shaped by the distribution of money, power, and resources”. Unmet social needs include financial distress, psychological and spiritual concerns, job security, food, housing and transportation needs, problems with communication and health literacy, and caregiver impact.
- The COVID-19 pandemic has prompted dramatic changes in the clinical care environment. These changes substantially affect how patients with gynecologic cancers interact with the health care system, and may require gynecologic cancer professionals to alter their approach to providing medical and surgical care. Additionally, healthcare institutions may call on gynecologic oncologists to represent the interests of their patients during deliberations regarding institutional allocation of scarce healthcare resources.
- The COVID-19 pandemic has consumed considerable resources and has impacted the delivery of cancer care. Patients with cancer may have factors which place them at high risk for COVID 19 morbidity or mortality. Highly immunosuppressive chemotherapy regimens and possible exposure to COVID-19 during treatment may put patients at additional risk. The Society of Gynecologic Oncology convened an expert panel to address recommendations for best practices during this crisis to minimize risk to patients from deviations in cancer care and from COVID-19 morbidity.
- Gynecologic oncologists have the unique opportunity of caring for patients in a broad range of surgical and medical settings. With increasing awareness of the opioid epidemic and the various factors that contribute to chronic opioid use, gynecologic oncologists must also better understand how to best address acute postoperative pain without unknowingly placing patients at risk for opioid misuse. This article examines the use of opioids in the acute surgical setting and provides clinical guidelines and various strategies to reduce opioid misuse.
- Approximately 40% of women with gynecologic malignancies are pre- or perimenopausal at the time of diagnosis [1,2]. Combined multimodality therapy including surgery, chemotherapy and/or radiation often results in induced menopause. The Society of Gynecologic Oncology and NCCN recommend prophylactic risk reducing surgery between ages 35–45, or at the completion of child bearing, depending on the specific germline mutation for women with Lynch syndrome, BRCA1 or BRCA2 mutations [3–5]. Induced menopause is defined by The North American Menopause Society as the cessation of menstruation following bilateral oophorectomy or iatrogenic ablation of ovarian function due to chemotherapy or pelvic radiation .
- Cannabis has been used for medicinal purposes across the world for centuries. It was included in the U.S. Pharmacopeia (Extractum Cannabis) in the mid-1800s and prescribed for a variety of conditions . By the early 20th century, states began to individually outlaw cannabis. This was at least in part due to racism in that the smoked form of the drug was introduced by Mexican immigrants . The federal government developed a series of statutes banning cannabis beginning in the 1930s. Medical cannabis was removed from the U.S.